[
    [
        {
            "time": "2018-10-11",
            "original_text": "【中投早知道】2018-10-11 10日晚公告精选丨贾跃亭所持乐视网股份累计被司法处置约2202万股",
            "features": {
                "keywords": [
                    "贾跃亭",
                    "乐视网",
                    "司法处置",
                    "还债"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "传媒"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【中投早知道】2018-10-11 10日晚公告精选丨贾跃亭所持乐视网股份累计被司法处置约2202万股",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-10-11",
            "original_text": "公告精选：贾跃亭所持约2202万股被司法处置用于还债；恒瑞医药董事、高管拟合计减持225万股",
            "features": {
                "keywords": [
                    "贾跃亭",
                    "乐视网",
                    "恒瑞医药",
                    "减持"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "传媒"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "公告精选：贾跃亭所持约2202万股被司法处置用于还债；恒瑞医药董事、高管拟合计减持225万股",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-11",
            "original_text": "恒瑞医药董监高减持股份计划公告",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "减持",
                    "董监高"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药董监高减持股份计划公告",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-11",
            "original_text": "恒瑞医药：董事及高管拟合计减持不超225万股 减持股份",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "减持",
                    "董事",
                    "高管"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药：董事及高管拟合计减持不超225万股 减持股份",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-11",
            "original_text": "【药讯】恒瑞又一肿瘤药获批临床，人福抑郁药获FDA批准",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "肿瘤药",
                    "临床",
                    "FDA",
                    "人福"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【药讯】恒瑞又一肿瘤药获批临床，人福抑郁药获FDA批准",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-11",
            "original_text": "银河生物和恒瑞参股公司获批Car-T细胞治疗临床试验",
            "features": {
                "keywords": [
                    "银河生物",
                    "恒瑞医药",
                    "Car-T",
                    "临床试验"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "银河生物和恒瑞参股公司获批Car-T细胞治疗临床试验",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-11",
            "original_text": "优先审评哪些产品最热？461个优先审评产品剖析",
            "features": {
                "keywords": [
                    "优先审评",
                    "医药产品",
                    "分析"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "优先审评哪些产品最热？461个优先审评产品剖析",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-10-11",
            "original_text": "【平安医药】行业动态跟踪报告：第三批抗癌药医保谈判落地，以价换量期待结果",
            "features": {
                "keywords": [
                    "平安医药",
                    "抗癌药",
                    "医保谈判",
                    "以价换量"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【平安医药】行业动态跟踪报告：第三批抗癌药医保谈判落地，以价换量期待结果",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-11",
            "original_text": "医药生物行业:上海药品挂网公开议价第三款pd1上市",
            "features": {
                "keywords": [
                    "医药生物",
                    "上海药品",
                    "挂网议价",
                    "pd1"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业:上海药品挂网公开议价第三款pd1上市",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]